EN | UA
EN | UA

Help Support

Back

Trial evaluated Zoledronate treatment in osteoporosis patients discontinuing Denosumab

Trial evaluated Zoledronate treatment in osteoporosis patients discontinuing Denosumab Trial evaluated Zoledronate treatment in osteoporosis patients discontinuing Denosumab
Trial evaluated Zoledronate treatment in osteoporosis patients discontinuing Denosumab Trial evaluated Zoledronate treatment in osteoporosis patients discontinuing Denosumab

What's new?

Irrespective of the timing, ZOL (Zoledronate) treatment is not sufficient to completely prevent loss of BMD (bone mineral density) in patients discontinuing DMAB (Denosumab).

A recent study demonstrated that in patients discontinuing DMAB after 4.6±1.6 years, a subsequent single infusion of 5 mg ZOL given six or nine months after the last DMAB injection or when bone turnover was increased, did not fully prevent increases in bone turnover and bone loss.


This randomized, open-label, interventional study aimed to investigate if treatment with ZOL could prevent increases in bone turnover and bone loss in patients previously treated with DMAB. It also determined if the timing of the administration after the last injection of DMAB influenced the outcome effect of ZOL.


The study included 61 participants with osteopenia who discontinued long-term treatment with DMAB to ZOL at three different intervals after the last DMAB injection. 59 patients completed the follow-up period. Patients were randomly assigned to receive ZOL six (6M group, n=20) or nine months (9M group, n=20) after the last DMAB injection or when bone turnover had increased (OBS; Observation group, n=21).


Using DXA (dual-energy x-ray absorptiometry) and bone turnover markers, the patients were monitored. The primary endpoints were changes in LSBMD (lumbar spine bone mineral density) six months after ZOL and the proportion of patients who failed to maintain BMD.


Six months after ZOL, LSBMD had decreased significantly by 2.1±0.9% (mean ± SEM), 4.3±1.1% and 3.0±1.1% in the 6M, 9M and OBS groups, respectively. 12 months after ZOL, LSBMD reduced by 4.8±0.7%, 4.1±1.1%, and 4.7±1.2% in the 6M, 9M, and OBS groups, respectively as depicted in Table 1:



In all groups, BMD loss above the least significant change was witnessed: At the spine: 6M:n=6 (30%), 9M: n=9 (45%), OBS: n= 9 (47%). At the total hip, the values were: 6M: n=1 (5%), 9M: n=5 (25%), OBS: n=2 (11%) as depicted in Table 2:


In the 6M group, p-CTX (p-cross-linked C-terminal telopeptide) declined initially but rapidly elevated thereafter. Six months after ZOL, p-CTX was 0.60±0.08 g/L.  In the 9M and OBS groups, p-CTX elevated rapidly. It was suppressed by ZOL but elevated again thereafter; p-CTX was 0.47±0.05 μg/L and 0.47±0.05 μg/L six months after ZOL, respectively. In the 9M group, incident vertebral fractures were observed in two women. Thus, ZOL treatment cannot fully prevent the loss of BMD in patients discontinuing DMAB.

Source:

Journal of Bone and Mineral Research

Article:

Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial

Authors:

Anne Sophie Solling et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: